Delays in treatment for psychosis can be associated with poorer outcomes.
While lithium has been the mainstay of treatment for decades, several other classes of medication have recently been used with varying degrees of success.
Atypical antipsychotic adjunctive therapy to mood stabilizers may be more effective than mood stabilizer monotherapy.
For the acute treatment of manic or mixed episodes in bipolar I disorder, the recommended starting and treatment dose is now 5-10mg twice daily.
This study included Medicaid patients taking medications to treat bipolar disorder, schizophrenia, or major depression with psychosis.
Lithium prescription rates for patients with bipolar disorder have declined during the last decade.
Group psychoeducation is a low-cost psychological intervention with specific clinical benefits in early bipolar disorder, if the focus of care is preventing future mania relapse and improving self-management, interpersonal function, and support.
The Mood Zoom questionnaire asks users to rate anxiety, elation, sadness, anger, irritability, and energy on a 7-point Likert scale
Programs conducted in early stages of bipolar disorder to improve cognition and functioning may boost cognitive reserve and thus, help prevent cognitive decline.
One line of future research in this area will be examining whether dorsal attention network connectivity predicts behavioral performance and emotional reactivity.
Approximately 2.5% of people worldwide are estimated to have bipolar spectrum disorders, which are a significant cause of neuropsychiatric disability.
Dr. Scott Zeller suggests it is time to move away from emergency intramuscular haloperidol.
Patients with comorbid bipolar disorder and ADHD may benefit from methylphenidate treatment, if it can be done without incurring the risk of mania.
Intra-subject variability in reaction time (ISVRT) is viewed as a promising behavioral endophenotype for bipolar disorder.
Until now, the majority of postmortem research that has examined functionally related gene sets has been limited to a single disorder or region of the brain.
By using the Washington Early Recognition Center Affectivity and Psychosis (WERCAP) questionnaire, investigators accurately predicted bipolar disorder or schizophrenia in more than 85% of patients.
Findings suggest that in families with 2 generations of direct progenitors with bipolar disorder, an increase in bipolar disorder severity in future generations is likely.
Treatment initiated in the early stages of bipolar disorder was found more effective than treatment in later stages.
Interaction of Proline and COMT Genotype Influences Negative Symptoms in Schizophrenia & Bipolar DisorderSeptember 27, 2016
The authors explored whether valproate (VPA) treatment effects vary by catechol-O-methyltransferase (COMT) genotype.
Brain-derived Neurotrophic Factor and its Precursor proBDNF as Diagnostic Biomarkers for Mood DisordersSeptember 12, 2016
mBDNF/proBDNF ratio could potentially serve as a novel biomarker for mood disorders.
Insights from the Global Burden of Disease Study 2013
The immune system dysregulation may lead to or exacerbate neuropsychiatric conditions such as bipolar disorder.
Until now, assessment of aerobic exercise capacity included expensive and time-consuming laboratory tests that do not necessarily accurately reflect patients' day-to-day physical functioning.
Irritability in Recovered Bipolar Disorder Patients Linked to Greater Morbidity, Depression RecurrenceAugust 22, 2016
Delayed depressive recovery occurred more in depressed patients with current irritability.
Direct comparison of white matter tracts between individuals with schizophrenia or bipolar disorder has not been performed to date.
Psychosocial and Demographic Predictors of Depression Among Individuals With Bipolar Disorder and SchizophreniaAugust 15, 2016
Bipolar disorder and schizophrenia are characterized by significant genetic overlap, as well as significant clinical presentation overlap.
The researchers quantified the transcript levels of GAD67, parvalbumin, somastatin, and Lhx6 in the prefrontal cortex.
Drug comparisons for mood disorders such as bipolar disorder, major depressive disorder, treatment resistant depression, premenstrual dysphoric disorder, and others.
Researchers found that many patients have disruptive symptoms for years before they receive proper treatment.
Investigators examined antibiotic use in patients with bipolar disorder, schizophrenia, and major depressive disorder.
Psychiatry Advisor Articles
- Naltrexone-Assisted Detox vs Buprenorphine Taper for Opioid Dependence
- Suicide Prevention and Intervention: Cross-Cultural Perspectives
- Pediatric Patients Should Undergo Electrocardiogram Assessment Before Antipsychotic Treatment
- Which Antidepressants May Cause Birth Defects?
- Best Practices for Treatment of Bipolar Disorder